1. Home
  2. GLTO vs WETH Comparison

GLTO vs WETH Comparison

Compare GLTO & WETH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$31.36

Market Cap

23.7M

Sector

Health Care

ML Signal

HOLD

WETH

Wetouch Technology Inc.

HOLD

Current Price

$1.70

Market Cap

26.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLTO
WETH
Founded
2011
1992
Country
Denmark
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.7M
26.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GLTO
WETH
Price
$31.36
$1.70
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$36.00
N/A
AVG Volume (30 Days)
207.8K
90.6K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
81.55
EPS
N/A
0.62
Revenue
N/A
$43,519,385.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.82
Revenue Growth
N/A
6.08
52 Week Low
$2.01
$0.76
52 Week High
$33.60
$3.68

Technical Indicators

Market Signals
Indicator
GLTO
WETH
Relative Strength Index (RSI) 70.94 37.09
Support Level $25.60 $1.75
Resistance Level $32.20 $2.04
Average True Range (ATR) 3.02 0.17
MACD 0.76 -0.04
Stochastic Oscillator 92.21 4.26

Price Performance

Historical Comparison
GLTO
WETH

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

About WETH Wetouch Technology Inc.

Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.

Share on Social Networks: